课题基金 / 基金详情

Factors that modify insulin action

Factors that modify insulin action
改变胰岛素作用的因素
批准号:
7996761
负责人:
MARIA G BUSE
金额:
$9.52万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-01-01 至 2010-03-31

项目摘要

项目成果

MARIA G BUSE的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):“葡萄糖毒性”解释了未控制的1型糖尿病患者的胰岛素抵抗,并有助于2型糖尿病患者的胰岛素抵抗。它是引起血管并发症的主要原因,是糖尿病患者发病和死亡的主要原因。细胞持续暴露于高糖环境会增加己糖胺合成途径的通量,从而促进O-GlcNAc转移酶(OGT)底物udp - n -乙酰氨基葡萄糖(UDP-GlcNAc)的产生。OGT催化O-GlcNAc对特定丝氨酸/苏氨酸残基的可逆单次加成。o - glcn酰化和o -磷酸化通常是相互作用的。我们最近首次确定了四个地点
英文摘要
DESCRIPTION (provided by applicant): "Glucose toxicity" accounts for insulin resistance in patients with uncontrolled type 1 diabetes and contributes to it in type 2 diabetes. It contributes to the vascular complications, the major causes of morbidity and mortality in diabetic patients. Sustained exposure of cells to high glucose increases flux via the hexosamine synthesis pathway, enhancing the production of UDP-N-acetyl glucosamine (UDP-GlcNAc), the substrate of O-GlcNAc transferase (OGT). OGT catalyzes the reversible, single addition of O-GlcNAc to specific Ser/Thr residues. O-GlcNAcylation and O-phosphorylation are often reciprocal. We have recently identified, for the first time, four sites of O-GlcNAcylation on IRS-1 (as well as 11 novel Ser/Thr phosphorylation sites) by mass spectrometry. Preliminary data suggest that O-GlcNAc may affect IRS-1 signal transduction. Our major objective in Spec. Aim 1 is to firmly establish whether the O-GlcNAc modification alters IRS-1 signaling. In in vitro studies Ser will be mutated to Ala at the four O-GlcNAc sites, singly and in combination, wild type and mutated IRS-1 will be expressed in HepG2 cells and in intact liver via adenovirus, and their interactions with IRS-1 binding partners in response to insulin or to IGF-1 studied. In in vivo studies endogenous mouse IRS-1 will be knocked out with shRNA adenovirus and substituted with wild type or mutant IRS-1-expressing adenovirus. The effect of these manipulations on glucose and insulin tolerance tests and the expression of hepatic gluconeogenic enzymes will be studied. In Spec Aim 2 studies will be continued in a model of high glucose/ low dose insulin-induced insulin resistance of glucose transport and Akt activation in 3T3-L1 adipocytes. Insulin signaling to PI(3)K is largely maintained, but Akt activation is markedly impaired. Recent data indicate that PTEN protein expression is increased and insulin stimulated PtdIns(3,4,5)P3 is diminished. Stimulation of PTEN expression is inhibited by rapamycin. mTORC-1 activation clearly plays a role, cPKC may contribute, but JNK does not. The mechanism of enhanced PTEN expression, mTORC-1 action and the role of cPKC will be investigated. Several mechanisms which may synergize with or be mediated by mTOR will be addressed, including dysregulation of actin dynamics and possible activation of a phosphoprotein phosphatase(s). The analysis of the modus operandi in this model will be contrasted with the insulin resistance of glucose transport elicited by exposing cells to FFA. Insights gained from this model will be applied to L-6 myotubes and to intact rats made insulin resistant by chronic hyperglycemia. Understanding how different excess nutrients modify insulin's signaling may lead to the rational development of novel therapeutic targets.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SMALL INSTRUMENTATION GRANT
BIOMEDICAL RESEARCH SUPPORT
BIOMEDICAL RESEARCH SUPPORT
BIOMEDICAL RESEARCH SUPPORT
海外基金